HRP20120032T1 - SPOJEVI TETRAHIDROCIKLOPENTA[b]INDOLA KAO MODULATORI ANDROGENSKIH RECEPTORA - Google Patents

SPOJEVI TETRAHIDROCIKLOPENTA[b]INDOLA KAO MODULATORI ANDROGENSKIH RECEPTORA Download PDF

Info

Publication number
HRP20120032T1
HRP20120032T1 HR20120032T HRP20120032T HRP20120032T1 HR P20120032 T1 HRP20120032 T1 HR P20120032T1 HR 20120032 T HR20120032 T HR 20120032T HR P20120032 T HRP20120032 T HR P20120032T HR P20120032 T1 HRP20120032 T1 HR P20120032T1
Authority
HR
Croatia
Prior art keywords
compound
salt according
cyano
cyclopropyl
alkyl
Prior art date
Application number
HR20120032T
Other languages
English (en)
Croatian (hr)
Inventor
Gavardinas Konstantinos
Edward Green Jonathan
Kondaji Jadhav Prabhakar
Paul Matthews Donald
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20120032T1 publication Critical patent/HRP20120032T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
HR20120032T 2006-11-20 2007-11-06 SPOJEVI TETRAHIDROCIKLOPENTA[b]INDOLA KAO MODULATORI ANDROGENSKIH RECEPTORA HRP20120032T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86648406P 2006-11-20 2006-11-20
PCT/US2007/083745 WO2008063867A2 (en) 2006-11-20 2007-11-06 Tetrahydrocyclopenta[b] indole compounds as androgen receptor modulators

Publications (1)

Publication Number Publication Date
HRP20120032T1 true HRP20120032T1 (hr) 2012-02-29

Family

ID=39415431

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20120032T HRP20120032T1 (hr) 2006-11-20 2007-11-06 SPOJEVI TETRAHIDROCIKLOPENTA[b]INDOLA KAO MODULATORI ANDROGENSKIH RECEPTORA

Country Status (36)

Country Link
US (1) US7968587B2 (OSRAM)
EP (1) EP2094658B1 (OSRAM)
JP (1) JP5399259B2 (OSRAM)
KR (1) KR101121471B1 (OSRAM)
CN (1) CN101541749B (OSRAM)
AR (1) AR063559A1 (OSRAM)
AT (1) ATE538091T1 (OSRAM)
AU (1) AU2007324046B2 (OSRAM)
BR (1) BRPI0719092B8 (OSRAM)
CA (1) CA2670340C (OSRAM)
CL (1) CL2007003182A1 (OSRAM)
CO (1) CO6190513A2 (OSRAM)
CR (1) CR10802A (OSRAM)
CY (1) CY1112284T1 (OSRAM)
DK (1) DK2094658T3 (OSRAM)
EA (1) EA015627B1 (OSRAM)
EC (1) ECSP099350A (OSRAM)
ES (1) ES2376048T3 (OSRAM)
HR (1) HRP20120032T1 (OSRAM)
IL (1) IL198410A (OSRAM)
JO (1) JO2800B1 (OSRAM)
MA (1) MA31072B1 (OSRAM)
MX (1) MX2009005251A (OSRAM)
MY (1) MY154547A (OSRAM)
NO (1) NO342531B1 (OSRAM)
NZ (1) NZ576296A (OSRAM)
PE (1) PE20081161A1 (OSRAM)
PL (1) PL2094658T3 (OSRAM)
PT (1) PT2094658E (OSRAM)
RS (1) RS52191B (OSRAM)
SI (1) SI2094658T1 (OSRAM)
TN (1) TN2009000189A1 (OSRAM)
TW (1) TWI398438B (OSRAM)
UA (1) UA98777C2 (OSRAM)
WO (1) WO2008063867A2 (OSRAM)
ZA (1) ZA200903096B (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5308458B2 (ja) 2008-02-22 2013-10-09 ラジウス ヘルス，インコーポレイテッド 選択的アンドロゲン受容体調節物質
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
KR101278788B1 (ko) * 2008-05-16 2013-06-25 일라이 릴리 앤드 캄파니 테트라히드로시클로펜타［ｂ］인돌 안드로겐 수용체 조절제
AR078862A1 (es) 2009-11-13 2011-12-07 Lilly Co Eli Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia
JP5964756B2 (ja) 2010-02-04 2016-08-03 ラジウス ヘルス，インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
MX342898B (es) 2010-05-12 2016-10-18 Radius Health Inc * Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol.
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
WO2012152741A1 (de) 2011-05-10 2012-11-15 Bayer Intellectual Property Gmbh Bicyclische (thio)carbonylamidine
CN103265479B (zh) * 2013-06-14 2017-12-08 南开大学 一种6‑氯甲基烟酸叔丁酯的合成方法
DK3834824T3 (da) 2014-03-28 2025-12-01 Univ Duke Behandling af en østrogenreceptor-positiv brystkræft under anvendelse af en selektiv østrogenreceptormodulator
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
DK3474841T3 (da) 2016-06-22 2022-05-09 Ellipses Pharma Ltd Fremgangsmåder til behandling af ar+-brystkræft
US20180185347A1 (en) 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
WO2018129419A1 (en) 2017-01-05 2018-07-12 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
CN113348163B (zh) 2019-02-12 2024-10-08 雷迪厄斯制药公司 方法和化合物
WO2021151905A1 (en) * 2020-01-27 2021-08-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds for the treatment of renal disease
US11986461B1 (en) * 2023-08-24 2024-05-21 King Faisal University 3-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-2-ol as an antitumor and antimicrobial compound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988820A (en) * 1986-02-21 1991-01-29 Bayer Aktiengesellschaft Cycloalkano(1,2-B) indole-sulponamides
GB8924392D0 (en) * 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
GB9008108D0 (en) * 1990-04-10 1990-06-06 Bayer Ag Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles
DE4027278A1 (de) * 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
DE4131346A1 (de) * 1991-09-20 1993-03-25 Bayer Ag Indolsulfonamid substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
EP1221439B1 (en) * 1999-10-14 2007-01-03 Kaken Pharmaceutical Co., Ltd. Tetrahydroquinoline derivatives
US7160909B2 (en) 2001-08-09 2007-01-09 Eli Lilly And Company Cyclopenta[b]indole derivatives as sPLA2 inhibitors
DE10164564B4 (de) * 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
WO2003097598A1 (en) * 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
US20060074124A1 (en) * 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
AU2005226759A1 (en) * 2004-03-03 2005-10-06 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
JP2008520674A (ja) * 2004-11-22 2008-06-19 スミスクライン ビーチャム コーポレーション Ｈｃｖインヒビター
EP1828195A2 (en) 2004-11-23 2007-09-05 PTC Therapeutics, Inc. Substituted phenols as active agents inhibiting vegf production
GT200600078A (es) 2005-02-17 2007-04-12 Derivados de indol, benzotiofeno, benzofurano e indeno cicloalquil condensados
SI1902026T1 (sl) 2005-06-24 2010-07-30 Lilly Co Eli Derivati tetrahidrokarbazola uporabni kot modulatorji androgenskega receptorja
WO2007047604A2 (en) 2005-10-18 2007-04-26 Elixir Pharmaceuticals, Inc. Sirt1 inhibition
WO2008019825A1 (en) 2006-08-14 2008-02-21 Santhera Pharmaceuticals (Schweiz) Ag Use of tricyclic indole derivatives for the treatment of muscular diseases
KR101278788B1 (ko) 2008-05-16 2013-06-25 일라이 릴리 앤드 캄파니 테트라히드로시클로펜타［ｂ］인돌 안드로겐 수용체 조절제

Also Published As

Publication number Publication date
AR063559A1 (es) 2009-02-04
KR101121471B1 (ko) 2012-02-28
CN101541749B (zh) 2013-03-27
HK1134089A1 (en) 2010-04-16
SI2094658T1 (sl) 2012-04-30
BRPI0719092A2 (pt) 2013-12-03
TWI398438B (zh) 2013-06-11
UA98777C2 (en) 2012-06-25
EA015627B1 (ru) 2011-10-31
ES2376048T3 (es) 2012-03-08
NO342531B1 (no) 2018-06-11
TW200827347A (en) 2008-07-01
IL198410A0 (en) 2010-02-17
ECSP099350A (es) 2009-06-30
CA2670340C (en) 2014-05-20
MX2009005251A (es) 2009-08-19
PL2094658T3 (pl) 2012-05-31
KR20090082229A (ko) 2009-07-29
PE20081161A1 (es) 2008-08-15
CL2007003182A1 (es) 2008-06-27
JP5399259B2 (ja) 2014-01-29
ZA200903096B (en) 2010-07-28
EP2094658A2 (en) 2009-09-02
US20100069404A1 (en) 2010-03-18
NZ576296A (en) 2011-11-25
CA2670340A1 (en) 2008-05-29
MA31072B1 (fr) 2010-01-04
IL198410A (en) 2013-09-30
CN101541749A (zh) 2009-09-23
BRPI0719092B8 (pt) 2021-05-25
PT2094658E (pt) 2012-02-22
BRPI0719092B1 (pt) 2020-08-18
MY154547A (en) 2015-06-30
AU2007324046B2 (en) 2012-04-05
CY1112284T1 (el) 2015-12-09
JP2010510231A (ja) 2010-04-02
NO20092103L (no) 2009-05-28
WO2008063867A2 (en) 2008-05-29
TN2009000189A1 (en) 2010-10-18
CO6190513A2 (es) 2010-08-19
WO2008063867A3 (en) 2008-07-31
JO2800B1 (en) 2014-03-15
US7968587B2 (en) 2011-06-28
EP2094658B1 (en) 2011-12-21
DK2094658T3 (da) 2012-02-13
RS52191B (sr) 2012-10-31
AU2007324046A1 (en) 2008-05-29
ATE538091T1 (de) 2012-01-15
EA200970500A1 (ru) 2009-10-30
CR10802A (es) 2009-07-13

Similar Documents

Publication Publication Date Title
HRP20120032T1 (hr) SPOJEVI TETRAHIDROCIKLOPENTA[b]INDOLA KAO MODULATORI ANDROGENSKIH RECEPTORA
JP2010510231A5 (OSRAM)
ES2707997T3 (es) Compuestos de benzotiazol y su uso farmacéutico
JP2016512844A5 (OSRAM)
CA2569396A1 (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2007002181A3 (en) Tetrahydrocarbazole derivatives useful as androgen receptor modulators (sarm)
ZA200508158B (en) Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics
JP5837936B2 (ja) アルキルスルフィニル置換チアゾリド化合物
EP3755699A1 (en) Shp2 phosphatase inhibitors and methods of use thereof
PE20061198A1 (es) Derivados de pirazol como inhibidores de cdk y gsk
CN114585623A (zh) 双[N-((5-氨基甲酰基)-1H-苯并[d]咪唑-2-基)吡唑-5-甲酰胺]衍生物和相关化合物作为STING（干扰素基因刺激物）激动剂用于治疗癌症
WO2007030777A3 (en) Amide and carbamate derivatives of alkyl substituted n-[4-(4-amino-1h-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamides and methods
JP2008525417A5 (OSRAM)
FI3786162T3 (fi) Bipyratsolijohdannaisia jak-inhibiittoreina
JP2006515858A5 (OSRAM)
HRP20191268T1 (hr) Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk
CA2535338A1 (en) Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
JP2014528450A5 (OSRAM)
HRP20150941T1 (hr) Derivati aminodihidrotiazina kao inhibitori bace u lijeäśenju alzheimerove bolesti
JPWO2007049532A1 (ja) アミノジヒドロチアジン誘導体
WO2007041365B1 (en) 3-cyclyl-2- (4-sulfamo yl-phenyl) -n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes
AR056186A1 (es) Compuesto de imidazo[1,2-a]piridinilo, su uso para la fabricacion de un medicamento y formulacion farmaceutica que lo comprende
JP2019500387A5 (OSRAM)
WO2009064747A3 (en) 4(-3-(-2-(phenyl) morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl) benzenesulfon amide derivatives and related compounds as modulators of ion channels for the treatment of pain
PT1891038E (pt) N-arilpirrolidinas substituídas como moduladores selectivos do receptor de androgénio